An interim analysis of a Phase 2 trial evaluating oral nalbuphine extended release for treating chronic cough in idiopathic pulmonary fibrosis

This Phase 2, randomized, double-blind, crossover, proof-of-concept trial examined the effects of an extended-release formulation of nalbuphine in 26 adult patients with IPF-related chronic cough. The primary endpoint was the percent change from baseline in hourly daytime cough frequency, which was objectively measured using the Vitalograph VitaloJAK digital cough monitor.